Recombinant Human ACE2 Protein

Binding assay, enzyme activity assay, ELISA, glycosylation analysis, antibody generation, hybridoma screening, western blotting, biotin/dye/bead conjugation, binder selection, crystallization, etc.

C-terminal his-tag

-20°C

Recombinant Human Angiotensin-converting Enzyme 2 (ACE2) with C-terminal His-tag, derived from the transfected human HEK293 cells. Datasheet

12352202

Gln18-Ser740 (Extracellular domain)

His-tag affinity purification by immobilized metal ion affinity chromatography (IMAC)

Figure 1. Deglycosylation of purified recombinant proteins. Purified proteins were untreated (Lane 2) or treated with Protein Deglycosylation Kit under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one major band at the expected size, thus indicating that the untreated recombinant protein (Lane 2) was glycosylated. Lane 1: Protein standard ladder (kDa) Lane 2: Untreated protein under reducing conditions Lane 3: Treated protein with deglycosylation enzymes under native conditions Lane 4: Treated protein with deglycosylation enzymes under reducing conditions

The product S1 RBD (Cat. 230-30162) was coated in 96 well plate and incubated with the serial diluted human ACE2 protein (Raybio, Cat. 230-30165). The bound ACE2 was detected by anti-ACE2 antibody using ELISA. The calculated EC50 is 4.23-9.26 ng/mL.